Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Arthritis Rheumatol. 2017 Jul 11;69(8):1623–1635. doi: 10.1002/art.40142

Table 1.

SLE patient characteristics and relative IFNβ mRNA level

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Ethnicity AA C C C AA AA
Age 33 57 50 46 64 33
Age of paired healthy donor 31 58 51 44 59 36
Sex F F F F F F
Passage 2 2 2 2 2 2
Total SLEDAI Score 6 6 2 7 0 2
anti-RNP (nl 0.0–0.9) >7.3 3.3 N.D.* 1.2 <0.2 >8.0
anti-Sm (nl 0.0–0.9) >8.0 0.2 N.D.* >8.0 <0.2 <0.2
anti-SM/RNP (nl 0.0–0.9) >8.0 >8.0 N.D.* >8.0 <0.2 1.2
anti-Ro (nl 0.0–0.9) >8.0 <0.2 7.4 >8.0 <0.2 >8.0
anti-La (nl 0.0–0.9) 1.5 <0.2 2 1.6 <0.2 0.5
anti-DNA (nl 0–4 U/mL) 17 14 194 24 3 <1
C3 (nl 90–180 mg/dL) 84 129 120 80 97 151
C4 (nl 10–40 mg/dL) 15 21 31 9 31 31
Relative IFNβ mRNA level compared to healthy controls (fold change) 3.4 3.1 2.7 4.3 1.7 2.9
*

Not determined.

HHS Vulnerability Disclosure